Cargando…
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes
As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence re...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353833/ https://www.ncbi.nlm.nih.gov/pubmed/32654078 http://dx.doi.org/10.1007/s00296-020-04629-x |